Navigation Links
Cardiome meldet Veröffentlichung positiver Ergebnisse aus Vergleichsstudie von Vernakalant IV mit Propafenon und Flecainid
Date:9/24/2013

Produkt- und Medikamentenentwicklung beziehen. Vorausschauende Aussagen unterliegen bekannten und unbekannten Risiken, Unwägbarkeiten und sonstigen Faktoren, die dazu führen können, dass sich tatsächliche Ergebnisse, Ereignisse oder Entwicklungen wesentlich von den zukünftigen Ergebnissen, Ereignissen oder Entwicklungen unterscheiden, auf die in vorausschauenden Aussagen implizit oder explizit Bezug genommen wird. Viele dieser Risiken, Unwägbarkeiten und sonstigen Faktoren sind Gegenstand unserer Überlegungen, die den von uns getätigten vorausschauenden Aussagen zugrunde liegen. Hierzu zählen unter anderem folgende: die allgemeinen Wirtschafts- und Geschäftsbedingungen in den Vereinigten Staaten, Kanada, Europa und anderen Regionen, in denen wir vertreten sind; die Marktnachfrage; technologische Veränderungen, die unsere bestehenden Produkte bzw. unsere Fähigkeit zur Entwicklung und Vermarktung zukünftiger Produkte beeinflussen könnten; der Wettbewerb; die bestehende Gesetzgebung und behördliche Bestimmungen, Veränderungen im Zusammenhang mit der bestehenden Gesetzgebung und behördlichen Bestimmungen sowie ein mögliches Nichtbefolgen dieser Vorgaben; die mögliche Kostenerstattung für Produkte und dazugehörige Therapien durch Regierungsstellen und sonstige externe Kostenträger; Nebenwirkungen oder unerwartete Verzögerungen in der präklinischen und klinischen Produktentwicklungsphase; nachteilige Ergebnisse im Zusammenhang mit der Sicherheit und/oder Wirksamkeit unserer Produkte; Entscheidungen von Gesundheitsbehörden bezüglich der Zulassung unserer Technologie und unserer Produkte sowie der jeweilige Zeitpunkt dieser Entscheidungen; der erhebliche Finanzmittelbedarf zur Ausweitung unserer Vermarktungsaktivitäten sowie weitere Faktoren aller Art, die unsere Leistung beeinflussen können. Zudem unterliegt unser Geschäft bestim
'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
2. Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Quebec , November 21, 2014 ... wechselt als Chief Commercial Officer zu KLOX ... SVP der Unternehmensentwicklung und Chief Financial Officer bestellt    ... Europa mit der Vermarktung seines jüngst zugelassenen Behandlungssystems zur ... Inc. ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, die ...
(Date:11/21/2014)... --  TRU-D SmartUVC LLC and its UK partners, Rapid ... robot, TRU-D SmartUVC, at FIS 2014 in Harrogate, ... at Stand 23. The conference, hosted by Federation ... largest infection-related event of its kind and brings together ... leading events of its type throughout the world. This annual ...
(Date:11/21/2014)... November 20, 2014 Offering a complete ... Sartorius Entris Balance promotion . The Sartorius Entris Balance ... durable, high accuracy, and easy-to-maintain balance entry level balance. ... It was designed to help customer’s bridge the gap ... balance that is very durable. Sartorius is the second ...
(Date:11/21/2014)... Alto, Calif. (PRWEB) November 20, 2014 ... a nonprofit, public policy research organization representing leading ... pharmaceutical firms, and PwC US today ... states in life sciences industry growth. The trend ... 2013. The 2015 California Biomedical Industry Report ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
... signed into law Senate Bill 338, which is designed ... in the way of University of Wisconsin researchers. , ... turn research ideas into potential business opportunities. He said ... faculty and staff try to start businesses based on ...
... San Francisco or Boston, and youre on the verge of investing ... right: The management team is in place, the business plan is ... a lawyer steps into the room, clears her throat and asks ... not write that check, she says, until you learn more about ...
... - Are state government information technology consolidation projects ... Miszewski, the CIO for the State of Wisconsin, has ... are not unusual for large state projects. He has ... government CIOs, but are cost overruns, implementation delays, and ...
Cached Biology Technology:Why repealing the shareholder wage lien law makes sense 2Why repealing the shareholder wage lien law makes sense 3State IT failures are not inevitable 2State IT failures are not inevitable 3State IT failures are not inevitable 4State IT failures are not inevitable 5
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/7/2014)... Calif. , Nov. 7, 2014  In conjunction with ... Police Departments, The Community Foundation of the Verdugos ... DNA JUSTICE PROJECT," a $250,000 initiative to keep ... initial phase. In its first six months of existence, the ... needed evidence support for local law enforcement. "Because ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... Dec. 6, 2010 Parascript, LLC, the image ... that its Signature Xpert was awarded best ... International Conference on Frontiers in Handwriting Recognition (ICFHR2010) ... 2010. Parascript was among seven participants representing a ...
... The season in which babies are born can have ... clocks function. That is the conclusion of a new ... Nature Neuroscience . The experiment provides the first ... and was conducted by Professor of Biological Sciences Douglas ...
... multiple sclerosis could be reversed by activating stem cells that ... has shown. Researchers from the Universities of Cambridge and ... known as myelin sheaths that protect nerve fibres ... showed how this mechanism can be exploited to make the ...
Cached Biology News:Parascript SignatureXpert Wins Forensic Signature Verification Competition 2Babies' biological clocks dramatically affected by birth light cycle 2Babies' biological clocks dramatically affected by birth light cycle 3Babies' biological clocks dramatically affected by birth light cycle 4Babies' biological clocks dramatically affected by birth light cycle 5Study reveals new possibility of reversing damage caused by MS 2
Assay Diluent Trial Pack, 4 x 100 mL...
... ZMD.474. Immunogen: Synthetic peptide derived ... mouse junctophilin-3. Specificity: Specific for ... protein. Reactivity: Mouse (positive controls: ... and heart tissues). Applications: Western ...
Rabbit anti-Junctophilin-4 (C-term)...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Biology Products: